KLRS

SEC source: 0001193125-26-374352 · ownership.xml · derivative · entry 1

Vandekop Amy O'Leary · CIK 0002146984 · VP, Corporate Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-26

F1 · derivative.exercise_date: The option was granted on August 27, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on August 1, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001193125-26-330530 · ownership.xml · derivative · entry 1

KEATING LAURIE · CIK 0001620743 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2036-07-31

F1 · derivative.exercise_date: The option was granted on August 1, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from August 1, 2026 through August 1, 2029, subject to continuous service.

SEC source: 0001193125-26-309047 · ownership.xml · derivative · entry 1

Bayko Liisa Ann · CIK 0002145720 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 220,000 shares

Expires 2036-07-19

F1 · derivative.exercise_date: The option was granted on July 20, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on July 20, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001193125-26-257564 · ownership.xml · derivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257556 · ownership.xml · derivative · entry 1

Ferrara Napoleone · CIK 0001744779 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257494 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257471 · ownership.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257465 · ownership.xml · derivative · entry 1

Dybbs Michael · CIK 0001601264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257462 · ownership.xml · derivative · entry 1

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001193125-26-257445 · ownership.xml · derivative · entry 1

PATTERSON LEONE D · CIK 0001233539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2036-06-02

F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 4

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital Partners, L.P.

Disclosed balance after: 19,408

F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3).

F8 · ownership.nature: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 3

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital GP, LLC

Disclosed balance after: 14,937

F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3).

F7 · ownership.nature: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 2

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 10,657,028

F3 · kind: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.

F4 · balance_after: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.

F5 · ownership.nature: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 2,224,147

F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.

F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.

SEC source: 0001193125-26-119707 · ownership.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: Due to an administrative error, the Reporting Person filed a Form 4 on March 27, 2025 reporting beneficial ownership of 1,925 shares, when in fact the amount of securities beneficially owned was 1,915. The number of shares beneficially owned by the Reporting Person following the transaction reported herein has been updated accordingly.

SEC source: 0001193125-26-117617 · ownership.xml · derivative · entry 1

Gall Matthew · CIK 0001816194 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2036-03-18

F1 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001193125-26-117618 · ownership.xml · derivative · entry 1

Oxtoby Andrew · CIK 0001765473 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 222,000

Underlying: Common Stock · 222,000 shares

Expires 2036-03-18

F1 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001193125-26-117616 · ownership.xml · derivative · entry 1

Feinsod Matthew · CIK 0001716950 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 135,000 shares

Expires 2036-03-18

F1 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001193125-26-119707 · ownership.xml · derivative · entry 2

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,800

Underlying: Common Stock · 60,800 shares

Expires 2036-03-18

F2 · derivative.exercise_date: The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0001231919-25-000652 · form4-12222025_091234.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 1,500,000

F1 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Samsara Opportunity GP and Dr. Akkaraju have voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of his or its respective pecuniary interest therein.

SEC source: 0001231919-26-000166 · form4-02182026_010226.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner

Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner

Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara Opportunity Fund, L.P.

Disclosed balance after: 1,979,847

F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.

F2 · balance_after: Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby.

F3 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001193125-25-262831 · ownership.xml · derivative · entry 1

Gall Matthew · CIK 0001816194 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,000

Underlying: Common Stock · 235,000 shares

Expires 2035-11-02

F1 · derivative.exercise_date: The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0000950170-25-053372 · ownership.xml · derivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053382 · ownership.xml · derivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,262

Underlying: Common Stock · 50,262 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0000950170-25-053339 · ownership.xml · derivative · entry 1

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053369 · ownership.xml · derivative · entry 1

PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053379 · ownership.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053358 · ownership.xml · derivative · entry 1

Dybbs Michael · CIK 0001601264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053368 · ownership.xml · derivative · entry 1

Ferrara Napoleone · CIK 0001744779 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-053347 · ownership.xml · derivative · entry 1

Oxtoby Andrew · CIK 0001765473 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 287,000

Underlying: Common Stock · 287,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0000950170-25-053338 · ownership.xml · derivative · entry 2

Feinsod Matthew · CIK 0001716950 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,000

Underlying: Common Stock · 101,000 shares

Expires 2035-04-09

F2 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0000950170-25-053338 · ownership.xml · derivative · entry 1

Feinsod Matthew · CIK 0001716950 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,551

Underlying: Common Stock · 70,551 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

SEC source: 0000950170-25-053330 · ownership.xml · derivative · entry 1

PATTERSON LEONE D · CIK 0001233539 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from April 3, 2025 through April 3, 2028, subject to continuous service.

SEC source: 0000950170-25-053318 · ownership.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-04-09

F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service.

SEC source: 0000950170-25-046263 · ownership.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,925

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.70 to $9.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2).

SEC source: 0000950170-25-041498 · ownership.xml · nonDerivative · entry 1

Ferrara Napoleone · CIK 0001744779 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 504,000

F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the Merger).

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer.

SEC source: 0000950170-25-041496 · ownership.xml · derivative · entry 3

PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,913

Underlying: Common Stock · 105,913 shares

Expires 2034-05-27

F4 · date: Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement.

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F5 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2023, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0000950170-25-041496 · ownership.xml · nonDerivative · entry 2

PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 100,800

F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the "Merger").

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F3 · ownership.nature: These securities are held directly by S&S New Hampshire Trust (the "S&S Shares") for the benefit of the reporting person's children. The reporting person may be deemed to have beneficial ownership over the S&S Shares. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000950170-25-041496 · ownership.xml · nonDerivative · entry 1

PATEL SAMIR CHANDRAKANT · CIK 0001277966 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,000

F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such, transaction, the "Merger").

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

SEC source: 0000950170-25-041494 · ownership.xml · derivative · entry 2

Feinsod Matthew · CIK 0001716950 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,224

Underlying: Common Stock · 28,224 shares

Expires 2034-07-22

F3 · date: Stock option assumed in connection with the closing of the Merger, in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement.

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F4 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of June 17, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0000950170-25-041494 · ownership.xml · nonDerivative · entry 1

Feinsod Matthew · CIK 0001716950 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,030

F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger").

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer (the "Exchange Ratio") and each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect the Exchange Ratio, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

SEC source: 0000950170-25-041485 · ownership.xml · derivative · entry 1

Oxtoby Andrew · CIK 0001765473 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 476,611

Underlying: Common Stock · 476,611 shares

Expires 2034-05-27

F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger").

F3 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of March 4, 2024, with 25% of the shares underlying the option having vested on March 4, 2025, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0000950170-25-041484 · ownership.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 11,444,503

F1 · date: Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger").

F2 · price: Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer.

F3 · ownership.nature: Shares held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-041475 · ownership.xml · derivative · entry 2

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,989

Underlying: Common Stock · 12,989 shares

Expires 2032-07-25

F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger").

F3 · price: Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0000950170-25-041475 · ownership.xml · derivative · entry 1

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,484

Underlying: Common Stock · 19,484 shares

Expires 2032-07-25

F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger").

F3 · price: Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger.

F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter.

SEC source: 0000950170-25-025634 · ownership.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,129

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-25-025633 · ownership.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,832

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-25-025630 · ownership.xml · nonDerivative · entry 1

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,517

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.06 to $10.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000950170-25-009205 · ownership.xml · nonDerivative · entry 2

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,623

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.81 to $10.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025.

SEC source: 0000950170-25-009205 · ownership.xml · nonDerivative · entry 1

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,628

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.81 to $9.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Reflects a 1-for-23 reverse split of the Issuer's Common Stock effected on January 16, 2025.